Wider Clinical Support for Kidney Perfusion

1 July 2015

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

Clinical support for wider application of kidney perfusion

Machine perfusion technology shown to improve outcomes not just in marginal organs

Lifeline Scientific (AIM: LSIC), the transplantation technology company, welcomes the publication in The American Surgeon of the meta-analysis study ('Study'): "Machine Perfusion: Not Just for Marginal Kidney Donors", which concludes that the benefits of machine perfusion should not be limited to marginal kidneys.

The Study was led by Dr. Robert M Cannon from the Department of Surgery at the University of Louisville, (Kentucky, USA) and retrospectively examines 36,323 patients undergoing kidney transplants in the US between 2005 and 2011, of which 9,882 received kidneys that underwent machine perfusion (MP). The remainder were preserved using the traditional method of static cold storage (SCS), i.e. ice-box preservation.

The study concludes that machine perfusion of donated kidneys, using technology such as the LifePort Kidney Transporter, was beneficial in reducing delayed graft function (DFG) in standard criteria donors (SCD), and not just in donation after cardiac death (DCD) or expanded criteria donors (ECD), where the benefits of machine perfusion are already widely recognised. DGF requires patients to endure renal dialysis post transplantation and is well established as being associated with costly post transplant complications, including increased hospitalisation and graft failure.

SCD kidneys tend to be from younger and healthier donors, whereas ECD kidneys are likely to come from older donor who may have an underlying medical condition that increases the risk of graft failure. DCD refers to donors that do not meet clinical criteria for brain death but in whom cardiac function has ceased before the organs were presented for transplantation.

The study used several methods to control the differences between the groups, but in a cohort of propensity-matched MP vs SCS recipients, where there were 8,929 patients each in the MP and CS groups, DGF occurred in 16.8 per cent of the MP group against 25.3 per cent of the SCS group.

Commenting David Kravitz, CEO of Lifeline Scientific, said:

"This is compelling news for patients, payors, and transplant centres as reportedly almost half of the deceased donor kidneys that present in North America every year come from standard criteria donors. Whilst there is wide spread clinical support for the benefits of using LifePort on ECD and DCD kidneys, the use of LifePort on SCD kidneys has not been universally adopted. These important findings show that using LifePort routinely for all donor kidneys, and not just marginal organs, could significantly benefit patient outcomes when compared to the common practice of simply storing donor kidneys in a box of ice.

"LifePort is the standard of care world-wide for machine perfusion of kidneys. In North America with placements in nearly 90% of the organ recovery programmes, we have observed that a number of leading transplant centres understand the benefits of machine perfusion for SCDs, and currently employ LifePort for all of their kidney transplantation procedures. We hope that this study will help convince many more centres to adopt protocols for the broader use of LifePort, beyond cases that involve marginal organs."

For more information on additional clinical evidence of the benefits of LifePort please visit:

http://www.organ-recovery.com/clinical_evidence.php

For further information:

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to help improve kidney preservation, evaluation and transport prior to transplantation. It has been widely studied in clinical trials throughout the world and is the standard of care for machine preservation of kidneys. Employed by surgeons in over 193 leading transplant programmes in 28 countries, LifePorts have preserved more than 50,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com

About LifePort Liver Transporter

LifePort Liver Transporter is modelled upon the clinically proven technology platform of LifePort Kidney Transporter and the Company's early HMP prototype successfully used in clinical transplant studies by surgeons at New York-Presbyterian Hospital/Columbia University Medical Center. LifePort Liver Transporter and the Company's proprietary machine preservation solution, Vasosol®, are in the process of US and European regulatory registrations. The system is designed to help improve outcomes in liver transplantation by enabling the clinical use of hypothermic machine perfusion, and has been developed in consultation with clinical and research teams specializing in liver transplantation at Columbia University Medical Center and the University of Chicago. The system employs a rugged, streamlined ergonomic design for ease of use and transportability from donor bedside to recipient operating room. For more information please visit: http://www.organ-recovery.com/pipeline.php